share_log

Chimerix Expects Dordaviprone Interim Overall Survival Data In 2025 And Final OS Data In 2026

Benzinga ·  May 1 07:13

Dordaviprone is an oral, first-in-class small molecule imipridone that selectively binds to the G-protein coupled dopamine receptor D2 (DRD2) and the mitochondrial protease ClpP.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment